- Drugs List
- Therapeutic Indications
- Precautions and Warnings
- Pregnancy and Lactation
- Side Effects
Oral formulation of molnupiravir.
Coronavirus disease 2019 (COVID-19) - treatment
Treatment of mild to moderate coronavirus disease 2019 (COVID-19) in adults with a positive SARS-COV-2 diagnostic test and who have at least one risk factor for developing severe illness.
Molnupiravir should be administered as soon as possible after a diagnosis of COVID-19 has been made and within 5 days of the onset of symptoms.
800mg (four 200mg capsules) every 12 hours for 5 days.
The safety and efficacy of molnupiravir when administered for periods longer than 5 days have not been established.
Additional Dosage Information
If a patient misses a dose within 10 hours of the time molnupiravir is usually taken, then the patient should take as soon as possible and resume the normal dosing schedule. If a patient misses a dose by more than 10 hours, the patient should not take the missed dose and instead take the next dose at the regularly scheduled time. The patient should not double dose.
Children under 18 years
Precautions and Warnings
Females of childbearing potential
Female: Contraception required during and for 4 days after treatment
Breastfeeding: Do not breastfeed during and for 4 days after treatment
Pregnancy and Lactation
Molnupiravir is contraindicated during pregnancy.
The manufacturer does not recommend taking molnupiravir during pregnancy. At the time of writing there is no data regarding the use of molnupiravir during pregnancy. Animal studies have shown reproductive toxicity.
Molnupiravir is contraindicated during breastfeeding.
The manufacturer does not recommend taking molnupiravir during breastfeeding and for four days after the last dose. It is unknown whether molnupiravir or any of its components are present in human breast milk, affect human milk production, or have effect on the breastfed infant. Animal studies have not been conducted.
It is strongly recommended that the UK National Poisons Information Service be consulted on cases of suspected or actual overdose where there is doubt over the degree of risk or about appropriate management.
The following number will direct the caller to the relevant local centre (0844) 892 0111
Information may be obtained if you have access to ToxBase the primary clinical toxicology database of the National Poisons Information Service. This is available via password on the internet ( www.toxbase.org ) or if this is unavailable at the backup site ( www.toxbasebackup.org ).
Last Full Review Date: November 2021
Summary of Product Characteristics: Lagevrio 200mg hard capsules. Merck Sharp & Dohme (UK) Limited. Revised November 2021.
NICE Evidence Services Available at: www.nice.org.uk Last accessed: 28 January 2022
Already a member? Log in
Medscape UK | Univadis prescription drug monographs & interactions are based on FDB Multilex Content
FDB Disclaimer : FDB Multilex is intended for the use of healthcare professionals and is provided on the basis that the healthcare professionals will retain FULL and SOLE responsibility for deciding what treatment to prescribe or dispense for any particular patient or circumstance.